Keep the details together.
- Product scope
- Wegovy injection: weight management in eligible adults.
- Route and preparation
- This entry covers subcutaneous Wegovy injection.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limits of the reference
- Check other products separately.
- Safety context
- Severe or persistent gastrointestinal symptoms: contact a clinician.
A note on reading the evidence.
Put a starting point and an ending point beside any result you want to discuss. If a claim uses words such as lasting or sustained, look for observations covering the period those words imply. A result at the last scheduled visit would answer a different question from a result measured after a later change in treatment. Your reading note can keep those periods separate without guessing what happened between them. This gives a care team a precise question about time, rather than a broad request to confirm that a result will last.
Questions to open a conversation.
- When does the observation period behind this claim begin and end?
- Does the wording suggest a longer period than the measurements cover?
- What later observations would help answer the question about lasting results?
Source reading.
- WEGOVYNLM · Checked
- Wegovy approvalFDA · Checked